HOME
ABOUT
RESEARCH
PRODUCTS
INVESTORS
- ASX ANNOUNCEMENTS
  - 2021
  - 2020
  - 2019
  - 2018
  - 2017
  - 2016
- PRESENTATIONS & VIDEOS
  - 2021
  - 2020
  - 2019
  - 2018
  - 2017
  - 2016
  - 2015
- REPORTS
- STOCK INFORMATION
- CORPORATE GOVERNANCE
MEDIA
CONTACT

HOME
ABOUT
RESEARCH
PRODUCTS
INVESTORS
- - ASX ANNOUNCEMENTS
  - - 2021
  - - 2020
  - - 2019
  - - 2018
  - - 2017
  - - 2016
- - PRESENTATIONS & VIDEOS
  - - 2021
  - - 2020
  - - 2019
  - - 2018
  - - 2017
  - - 2016
  - - 2015
- - REPORTS
- - STOCK INFORMATION
- - CORPORATE GOVERNANCE
MEDIA
CONTACT

PRESENTATIONS

PRESENTATIONS

AGM Presentation - Non-deal Roadshow

November 2018

Investor Presentation - Non-deal Roadshow

September 2018

SUBSCRIBE

Leave this field empty if you're human:

Zelira TherapeuticsFollow

3 Jun

Zelira Therapeutics is pleased to announce it has licensed its ZTL-106 proprietary cannabinoid formulation to Levin Health for a chronic pain treatment clinical trial on retired athletes.

Read our full ASX announcement here: http://ow.ly/DuPY50F2As5

Twitter 1400600755057344513

PRESENTATIONS

AGM Presentation

November 2018

AGM Presentation - Non-deal Roadshow

November 2018

Investor Presentation - Non-deal Roadshow

September 2018

Investor Presentation

February 2017

AGM Presentation

November 2017

Investor Presentation

November 2016

Investor Presentation

December 2015